Israeli company Alma Lasers, a leading player in China’s skin rejuvenation market, is undertaking an aggressive expansion into South Korea, viewing the country as a strategic market for its brand image. “Korea is a very important market. Being here is not only for revenue -- this is a market that we believe is a bridge to other markets in Asia,” said Lior Dayan, CEO of Sisram Medical, Alma’s parent company, in a conference call interview with The Korea Herald. “When

Industry Dec. 3, 2019

Nexon’s V4 and Zabob Studio’s Coin Princess won November’s G-Rank Game of the Month and Challenge Seoul award, respectively, the company said Friday.The G-Rank awards ceremony took place at OGN E-sports Stadium in Sangam-dong, Seoul, Thursday. November’s game, V4, is a mobile MMORPG made using Unreal Engine 4. It boasts high-end graphics, a vast virtual combat field and character customizing features that reportedly won many fans. Challenge Seoul award winner Coin Princes

Industry Nov. 29, 2019

Kakao’s Klaytn has ambitions to become the world’s biggest public blockchain consortium, said Kakao CEO Yeo Min-soo, Thursday, at the first Klaytn Governance Council Summit held in Seoul.“Currently, Klaytn’s expansion is centered in Asia, but it will gradually spread, in the end becoming the best global blockchain platform. To that end, we will not spare any investment and implore the Governance Council members to actively join in on the growth of our ecosystem,” sa

Industry Nov. 28, 2019

진행자: 임정요, Kevin Lee Selzer1. Korea, ASEAN adopt joint vision for cooperation기사 요약: 부산에서 열린 한아세안 특별 정상회담에서 참가국들 자유무역을 약속했다.아이튠즈(아이폰): https://itunes.apple.com/kr/podcast/koliaheleoldeu-paskaeseuteu/id686406253?mt=2팟빵 (안드로이드): http://www.podbbang.com/ch/6638[1] BUSAN – The ASEAN-ROK Commemorative Summit wrapped up Tuesday with the leaders agreeing to expand economic, political and social cooperation among the countries. *wrap up: 끝마치다*expand: 확장하다[2] “Advancement of the ASEAN is Korea&

Podcast Nov. 27, 2019

South Korea’s NCSoft launched Lineage2M, mobile version of the massively multiplayer online role-playing PC game Lineage 2, at midnight Tuesday. The MMORPG is the game company’s first new title in two years that is hoped to boost its annual revenue past the 2 trillion won ($1.7 billion) mark to join its competitors Nexon and Netmarble.Prior to the launch, Lineage2M topped the popularity list on both Google Play and App Store. Advance sign-ups for the game notched 7.38 million, a reco

Industry Nov. 27, 2019

SK Biopharmaceuticals has a full value chain ready for its newly approved partial onset seizure epilepsy drug Xcopri, said the company’s CEO Cho Jeong-woo, Tuesday. Beginning from compound discovery to preclinical trials, clinical trials and product approval in the US, SK Biopharmaceuticals has directly overseen every step of Xcopri’s commercialization. Now it will continue to directly handle local marketing and sales from the second quarter of 2020, said Cho during a press conferenc

Industry Nov. 26, 2019

Celltrion said Tuesday its infliximab biobetter Remsima SC has received the European Medicines Agency’s approval for sales in the continent. Remsima SC’s main target patients are those who are resistant to original TNF-a inhibitors such as Humira (adalimumab) and Enbrel (etanercept).  While infliximab currently takes up only 9 percent of the rheumatoid arthritis treatment market, the rate of patients who are prescribed a different medication -- apart from adalimumab and etanerce

Industry Nov. 26, 2019

When 93-year-old Korean pharmaceutical firm Yuhan signed a collaboration deal with Johnson & Johnson’s subsidiary Janssen a year ago, it excited bio investors here and abroad. The transaction, reaching up to 1.4 trillion won ($1.19 billion), was the second biggest in the history of Korean biopharma research and development at the time. Janssen was interested in Yuhan’s lazertinib pipeline for third-generation lung cancer. Since then, Gilead signed a deal worth 878 billion won to

Industry Nov. 26, 2019

Biotech startup Bridge Biotherapeutics is on its way to becoming the first Kosdaq-listed no-research, development-only company in Korea by the end of this year, the company said Friday.This is the company’s third attempt at making an initial public offering, and more promising than the previous two attempts on the back of the record 1.5 trillion-won ($1.27 billion) licensing out to Germany’s Boehringer Ingelheim in July. In a press conference held at Conrad Seoul, CEO Lee Jung-kue sa

Industry Nov. 22, 2019

A new South Korean anti-epileptic drug will be available in the US from as early as April. The US’ Food and Drug Administration has approved SK Biopharmaceuticals’ anti-epileptic drug XCOPRI (Cenobamate), officials said Friday. The product will be available in the second quarter of 2020 after review by the US Drug Enforcement Administration.The marketing and sales process will be overseen by SK Life Science, the US subsidiary of SK BIopharmaceuticals based in Paramus, New Jersey. XCO

Industry Nov. 22, 2019

CJ Healthcare said Thursday it will export its original gastroesophageal reflux disease drug to Thailand’s Pond’s Chemical. K-CAB Tab (tegoprazan) is listed as the 30th new drug developed by a Korean company. It acquired commercial approval from South Korea’s Ministry of Food and Drug Safety in 2018 and was launched here in March 2019. Since then, the drug has raked in 18.7 billion won ($15.8 million) in sales. K-CAB Tab is already being exported to 17 countries including China

Industry Nov. 21, 2019

LG’s IT solutions affiliate LG CNS and Kakao’s blockchain subsidiary Ground X joined hands with a view to expanding the use of blockchain and applying it to diverse business areas, the firms said Thursday.The two companies agreed to a strategic partnership to build mutually compatible infrastructure. Ha Tae-Seok, the leader of LG CNS’ future strategic business division, and Kakao Ground X CEO Han Jae-seon attended a signing ceremony at the LG CNS headquarters within LG Science

Industry Nov. 21, 2019

The clock has started ticking for the approval process of Samsung Bioepis’ fifth biosimilar in the US. The company said Wednesday that the US Food and Drug Administration has agreed to review the license application it submitted in September for SB8, a biosimilar candidate referencing Avastin (bevacizumab).  Avastin is a blockbuster biologics drug of Roche that prevents tumor growth by blocking blood supply. It inhibits a protein called vascular endothelial growth factor that creates

Industry Nov. 20, 2019

With South Korea’s market for health supplements growing, demand for female health-oriented probiotics is also expected to rise. Yuhan Care, a health supplement and beauty spinoff of Yuhan Corp., held a press event Tuesday to introduce the market’s outlook and the technology behind its newly launched UREX probiotics product, Inner Flora. The man behind the development of probiotics was invited to speak on the matter.At the event, Gregor Reid, the first scientist to discover the benef

Industry Nov. 19, 2019

The American Chamber of Commerce in Korea and Amway Korea will host the second Women’s Leadership Forum 2019 in Seoul on Wednesday to examine female leadership here and discuss ways to foster gender balance. “Policy support is needed to promote women’s economic activities and startups. We hope this forum will serve as an opportunity to reconsider ways to improve female leadership in corporates and foster next-generation female talent,” AmCham Chairman and CEO James Kim sa

Industry Nov. 19, 2019